Mechanism, developer, headline trial result, sizes, and starting price. Regulatory status is shown on every row — investigational means investigational.
| Compound | Mechanism | Developer | Headline trial result | Sizes (CAD) | From | |
|---|---|---|---|---|---|---|
| Semaglutide FDA-APPROVED |
GLP-1 receptor agonist The active ingredient in Ozempic and Wegovy — the original once-weekly weight-loss medicine. | Novo Nordisk | 14.9% mean weight loss at 68 weeks (STEP-1, 2.4 mg weekly) |
5mg ($14), 10mg ($21), 20mg ($31), 50mg ($53) | $14 | View → |
| Tirzepatide FDA-APPROVED |
Dual GIP / GLP-1 receptor agonist The active ingredient in Mounjaro and Zepbound — the newer, stronger once-weekly weight-loss medicine. | Eli Lilly | 20.9% mean weight loss at 72 weeks (SURMOUNT-1, 15 mg weekly) |
10mg ($26), 30mg ($50), 60mg ($77), 100mg ($140) | $26 | View → |
| Mazdutide APPROVED (CHINA) |
Dual GLP-1 / glucagon receptor agonist A once-weekly weight-loss medicine already approved in China — still experimental in Canada and the US. | Innovent Biologics / Eli Lilly | 18.55% mean weight loss at 60 weeks (GLORY-2 phase 3, 9 mg weekly) |
5mg ($36), 10mg ($72) | $36 | View → |
| Retatrutide PHASE 3 |
Triple GIP / GLP-1 / glucagon receptor agonist An experimental medicine that works three ways at once — in late-stage testing, not approved anywhere yet. | Eli Lilly | 24.2% mean weight loss at 48 weeks (phase 2, 12 mg weekly — NEJM 2023) |
10mg ($37), 30mg ($77), 60mg ($104), 100mg ($162) | $37 | View → |
| Survodutide PHASE 3 |
Dual glucagon / GLP-1 receptor agonist An experimental medicine that curbs appetite and boosts calorie burn — in late-stage testing. | Boehringer Ingelheim / Zealand Pharma | Phase 3 SYNCHRONIZE-1 and -2 trials underway in obesity |
2mg ($50), 5mg ($90), 10mg ($153), 15mg ($216) | $50 | View → |
| Cagrisema PHASE 3 |
Amylin analogue + GLP-1 (fixed-dose combination) Two weight-loss medicines in one shot — an amylin drug plus a GLP-1, combined. | Novo Nordisk | 22.7% mean weight loss at 68 weeks (REDEFINE-1 phase 3, cagrilintide 2.4 mg + semaglutide 2.4 mg weekly) |
10mg ($55), 20mg ($95) | $55 | View → |
| VK2735 PHASE 3 |
Dual GIP / GLP-1 receptor agonist Viking’s dual-action weight-loss drug — the same two pathways as tirzepatide, with the fastest onset ever reported. | Viking Therapeutics | 14.7% mean weight loss at 13 weeks (VENTURE phase 2, 15 mg weekly — no plateau observed) |
10mg ($47), 20mg ($79) | $47 | View → |
| Cagrilintide PHASE 3 |
Long-acting amylin analogue An experimental appetite medicine that works differently from the GLP-1 shots — in late-stage testing. | Novo Nordisk | 10.8% mean weight loss at 26 weeks (phase 2, 4.5 mg weekly) |
2mg ($28), 5mg ($36), 10mg ($68) | $28 | View → |
| Eloralintide PHASE 2 |
Amylin analogue (once-weekly) An experimental once-weekly appetite medicine in earlier testing — one to watch. | Eli Lilly | Phase 2 results presented at EASD 2026 |
20mg ($54), 50mg ($140) | $54 | View → |
| EloraTZP PHASE 1 |
Amylin analogue + dual GIP/GLP-1 (combination) An experimental combo shot — an amylin drug stacked on tirzepatide. Very early testing. | Eli Lilly | 17% mean weight loss at 16 weeks (phase 1, eloralintide 3 mg + tirzepatide 5 mg weekly) |
16mg ($47), 32mg ($77) | $47 | View → |
Trial figures are mean weight change in the cited trial populations — see each product page and the science guide for context. “FDA-approved” refers to the medicine; every vial on this site is sold strictly as a research chemical.
